Abstract
Neurotransmitter deficits are heterogeneous in patients with Parkinson’s disease. Compounds with broad modes of actions are suitable candidates to improve the individual variable expression of motor and non-motor symptoms, which result from this disease-related altered neurotransmission. Therefore, safinamide may be an ideal agent for the treatment of Parkinson’s disease. The pharmacological profile of safinamide is characterized by reversible monoamine oxidase B inhibition and modulation of voltage-dependent sodium and calcium channels with consecutive decline of glutamate release. Safinamide provided beneficial effects on motor symptoms. Oral administration of safinamide one time daily with a dose range from 50 to 100 mg was well tolerated and safe. Safinamide has a better side effect profile in terms of clinical handling, safety, and tolerability than dopamine agonists. Safinamide with its broad modes of action influences the heterogeneous, altered brain neurochemistry in Parkinson’s disease. Safinamide supplements the armamentarium of drug therapy of Parkinson’s disease. It will help to spare not only levodopa but also dopamine agonists during long-term therapy in suitable patients.
This is a preview of subscription content, log in via an institution to check access.
References
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014a;29(2):229–37.
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014b;29(10):1273–80.
Deeks ED. Safinamide: first global approval. Drugs. 2015;75(6):705–11.
Di Stefano AF, Rusca A. Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn Schmiedeberg’s Arch Pharmacol. 2011;384(6):505–15.
Fariello RG, McArthur RA, Bonsignori A, Cervini MA, Maj R, Marrari P, et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther. 1998;285(2):397–403.
Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19(5):508–14.
Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord. 2011;26(5):813–8.
Krosser S, Marquet A, Gallemann D, Wolna P, Fauchoux N, Hermann R, et al. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos. 2012;33(9):550–9.
Leuratti C, Sardina M, Ventura P, Assandri A, Muller M, Brunner M. Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology. 2013;92(3–4):207–16.
Loprete L, Leuratti C, Cattaneo C, Thapar MM, Farrell C, Sardina M. Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson’s disease. Pharmacol Res Perspect. 2016;4(5):e00251.
Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50(1):77–85.
Muhlack S, Musch P, Konietzka S, Woitalla D, Przuntek H, Müller T. Impact of oral fast release amantadine on movement performance in patients with Parkinson’s disease. Pharmaceutics. 2010;2(3):313–20.
Müller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56(3):251–61.
Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941–9.
Podurgiel S, Collins-Praino LE, Yohn S, Randall PA, Roach A, Lobianco C, et al. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacol Biochem Behav. 2013;105:105–11.
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):216–24.
Schnitker J, Müller T. Meta-analysis of placebo-controlled clinical trials of safinamide and entacapone as add-on therapy to levodopa in the treatment of Parkinson’s disease. Eur Neurol Rev. 2015;10(1):15–22.
Seithel-Keuth A, Johne A, Freisleben A, Kupas K, Lissy M, Krosser S. Absolute bioavailability and effect of food on the disposition of safinamide immediate release tablets in healthy adult subjects. Clin Pharmacol Drug Dev. 2013;2(1):79–89.
Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson’s disease. Mov Disord. 2010;25(4):508–10.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Müller, T. (2020). Safinamide for Treating Parkinson’s Disease. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_236-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_236-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine